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Background: The optimal initial local treatment for patients with Graves’ ophthalmopathy (GO) is not fully
characterized. The purpose of this retrospective study is to describe the clinical outcomes of RT as initial local
therapy for GO and define predictors of the need for post-RT salvage bony decompressive surgery.
Methods: 91 patients with active GO and without prior surgery were treated with RT as initial local therapy
between 01/1999 and 12/2010, with a median follow-up period of 18.3 months (range 3.7 - 142 months). RT dose
was 24 Gy in 12 fractions. 44 patients (48.4%) had prior use of steroids, with 31 (34.1%) being on steroids at the
initiation of RT. The most common presenting symptoms were diplopia (79%), proptosis (71%) and soft tissue
signs (62%).
Results: 84 patients (92.3%) experienced stabilization or improvement of GO symptoms. 58 patients (64%)
experienced improvement in their symptoms. 19 patients (20.9%) underwent salvage post-RT bony decompressive
surgery. Smoking status and total symptom score at 4 months were independent predictors of post-RT bony
decompression with odds ratios of 3.23 (95% CI 1.03 – 10.2) and 1.59 (95% CI 1.06 – 2.4), respectively. Persistent
objective vision loss at 4 months post-RT was the most important symptom type in predicting salvage
decompression. Chronic dry eye occurred in 9 patients (9.9%) and cataracts developed in 4 patients (4.4%).
Conclusions: RT is effective and well tolerated as initial local therapy for active GO, with only 21% of patients
requiring decompressive surgery post RT. Most patients experience stabilization or improvement of GO symptoms,
but moderate to significant response occurs in the minority of patients. Smoking status and total symptom severity
at 4 months, primarily persistent objective vision loss, are the primary determinants of the need for post-RT salvage
bony decompression. Patients who smoke or present with predominantly vision loss symptoms should be advised
as to their lower likelihood of symptomatic response to RT and their increased likelihood of requiring post-RT
decompressive surgery.
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Graves’ disease is an autoimmune disease characterized
by the production of autoantibodies that activate the
thyroid stimulating hormone (TSH) receptor. This
receptor is primarily located in thyroid tissue, but also
has been found to be expressed in the connective
and adipose tissue of retrobulbar contents [1]. Graves
ophthalmopathy (GO) is characterized by enlargement
and inflammation of the retrobulbar contents, primarily
the extraocular eye muscles (EOM). Mucinous material
is deposited in the EOM, leading to an inflammatory
and fibrotic reaction involving fibroblast proliferation
and lymphocyte infiltration [2]. Additionally, some patients
with GO produce autoantibodies that interact with
orbital fibroblasts, leading to the secretion and depos-
ition of collagen and mucopolysaccharides behind the
globe that result in increased intraorbital pressure. The
combination of both processes produces the typical
spectra of GO symptoms, including proptosis, EOM
dysfunction leading to diplopia, periorbital edema, and
compressive optic neuropathy in more severe instances.
Approximately 20 – 25% of patients with Graves’ disease
will present with clinically significant GO, although only
about 3 – 5% will develop severe disease [3].
Radiation therapy (RT) is an established modality
for the treatment of moderate to severe GO. Its
mechanism of action is primary through non-specific
anti-inflammatory effects, as well by affecting highly
radiosensitive infiltrating lymphocytes and possibly re-
ducing fibroblast proliferation and mucopolysaccharide
secretion [4]. Other modalities used in the treatment
of GO include systemic corticosteroids, surgery, or a
combination of therapies. The optimal treatment algo-
rithm for patients without progressive vision loss is
not well defined. Previous clinical trials have demon-
strated that orbital RT is better tolerated and as ef-
fective as oral steroids [5], and that the combination
of these methods is more effective than either therapy
alone [6,7].
We defined local therapy as any non-systemic inter-
vention directed towards orbital symptoms, i.e. RT,
surgery, or steroid drops. Oral steroids were considered
systemic therapy for orbital symptoms. At our institu-
tion, we have adopted the policy of treating patients
who have moderate to severe GO with radiation ther-
apy with or without steroids as initial local therapy
in order to avoid surgical intervention. The purpose
of this retrospective review is to assess the efficacy of
RT with or without steroids as initial local therapy
for clinically significant GO, report the rate of sal-
vage decompressive surgery using this treatment
paradigm, and describe factors that are associated
with lack of clinical response and the need for salvage
bony decompression.Methods
Patients
We reviewed the medical records of 102 consecutive
patients treated in our department for GO between
01/1999 and 12/2010. 3 patients were lost to follow-up
prior to 4 months post-RT and were excluded. 8 add-
itional patients had undergone orbital/lid surgery prior
to RT and were excluded. This left 91 patients without
prior surgery who were treated with RT with or with-
out steroids as initial local therapy. The diagnosis of
GO was made prior to referral to our department and
patients were generally followed in conjunction with
oculoplastic surgeons. GO signs and symptoms were
classified into 5 general categories based upon the
NOSPECS classification system [8]: soft tissue, prop-
tosis, EOM dysfunction, corneal involvement, and sight
loss. However, due to known limitations of the NOS-
PECS classification system [9], we included additional
symptom categories of diplopia, orbital pain, and tear-
ing in our evaluation. Each category, except for tear-
ing, was assigned a score of 0 – 2 based on severity of
symptoms, with scores of 0, 1, and 2 representing
no symptoms, mild to moderate symptoms, and severe
symptoms, respectively. Tearing was assigned a score
of 0 (no tearing) or 1 (tearing). Total disease severity
score was the cumulative score across all listed cat-
egories and ranged from 0 to 13. Follow-up with both
radiation oncology and oculoplastic surgery generally
occurred at 1 month and 4 months post RT, and then
every 6 months thereafter unless clinically indicated at
an earlier time point. In the absence of progressive
symptoms, a decision to undertake surgery was gener-
ally made following the 4 month follow-up visit. For
the purpose of this study, GO symptoms were retro-
spectively scored prior to RT, at 1 month, and at
4 month post-treatment according to the previously
described scoring system.
Response to RT was based on category and total sever-
ity score differences between the baseline scores and
4 month post-treatment scores, which was calculated
as [(baseline score - 4 month score)/baseline score].
Overall response was based on total severity score dif-
ference and categorized as follows: score difference
< 0% - progression, score difference > 0 to ≤ 10% - no
response (NR), 10% to ≤ 33% difference - mild response,
> 33% to ≤ 66% difference - moderate response, > 66%
difference - significant response. Stabilization or improve-
ment of GO symptoms was defined as an overall response
of≥ 0%. Individual symptom category response was
defined as complete (CR) if the symptom completely
resolved by 4 months, or as partial (PR) if there was an
improvement in symptoms without complete resolution.
Institutional review board approval was obtained for
this study.
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All patients were treated with a standardized approach
using linear accelerator based external beam radiation
therapy. Patients were immobilized supine on the treat-
ment couch with an Aquaplast mask (WFR/Aquaplast
Corp., Wyckoff, NJ) and treatment planning was per-
formed using the Eclipse platform (Varian Medical
Systems, Palo Alto, CA). A high resolution, thin slice
(0.625 mm slice thickness) CT scan without contrast
was obtained for treatment planning. All patients were
planned with CT based 3-dimensional conformal plan-
ning using multileaf collimation for field shaping. The
treatment isocenter was generally placed behind the lens
in order to half beam block the anterior divergence and
minimize dose to the lens. The clinical target volume
(CTV) was contoured and encompassed the retrobulbar
contents including the EOM and retrobulbar fat. Other
contoured structures included the globes, lenses, optic
nerves, and brain. The distance from the CTV to block
edge was typically 1.5 to 2 cm, except anteriorly, where
the field edge was intentionally set to exclude direct
irradiation of the lens. Opposed lateral 6 MV beams
were generally used for treatment, with wedges
employed to maintain dose homogeneity within the
target volume. All patients received 24 Gy given in 12
fractions over a 2.5 to 3 week period prescribed to the
97 – 100% isodose line.
Statistical analysis
Descriptive statistics were compiled to characterize the
patient population. Logistic regression analysis was per-
formed using baseline clinical factors and response to
RT to determine predictors of orbital decompression
after RT as well as complete steroid taper by 2 months
post-treatment in patients using steroids at the initiation
of RT. A p-value of ≤ 0.05 was considered significant;
all tests of significance were two-sided. Predictors with
a p-value ≤ 0.07 in univariate logistic analysis were
included in the multivariate model. All analyses were
carried out using the SPSS version 19.0 statistical soft-
ware package (IBM Inc., Armonk, NY).
Results
Patient characteristics
Ninety-one patients with a median age of 55 years
(range 29 – 84 years) were treated with a median follow-
up period of 18.3 months (range 3.7 - 142 months).
Sixty-one patients (67%) were followed for at least 1 year
post-RT. Sixty-seven patients (73.6%) had previous thy-
roid ablation treatment, including thyroidectomy in 14
(15.4%), radioactive iodine in 52 (57.1%), and both in
1 patient (1.1%). Forty-four patients (48.4%) had prior
use of steroids, with 31 (34.1%) being on steroids at the
initiation of RT. The minority of patients (29.7%) werecurrent smokers at the time of RT. Median total symp-
tom score prior to RT was 6 (range 1 – 12). The most
common presenting symptoms were diplopia (79.1%),
followed by proptosis (71.4%) and soft tissue signs
(61.5%). Disease severity was categorized by the number
and severity of presenting symptoms in combination
with the clinical criteria of the Dean McGee Eye Insti-
tute [10]. Most patients presented with mild (30.8%)
or moderate GO (61.5%), with severe GO symptoms
in only 7 patients (7.7%). See Table 1 for additional
patient characteristics.
Symptom response
The vast majority of patients (92.3%) experienced
stabilization or improvement of their GO symptoms.
Median total symptom score prior to RT, at 1 month,
and at 4 months was 6 (range 1 – 12), 4 (range 0 – 11),
and 3 (range 0 – 10), respectively. Overall response was
NR for 26 patients (28.6%), mild response for 21 patients
(23.1%), moderate response in 30 patients (33%), and
significant response in 7 patients (7.7%). Seven patients
(7.7%) experienced worsening of GO symptoms. Overall,
58 patients (63.7%) experienced a response in their total
symptom score by 4 month evaluation. Response to RT
by symptom category can be seen in Table 2. Pain,
EOM, and tearing symptom categories had the highest
CR rates of 65.8%, 27.7%, and 25.5%, respectively. Pain
and tearing also had the highest symptom improvement
rates (combined CR/PR) of 73.7% and 62.7%, respect-
ively. Objective vision loss and proptosis were the most
refractory to RT, with response rates (combined CR/PR)
of 37.1% and 41.5%, respectively. Of the 31 patients who
were on steroids at the initiation of RT, 23 (74.2%) were
able to be tapered completely off by 2 months post-RT.
Univariate logistic regression analysis was performed to
determine potential predictors of complete steroid taper-
ing by 2 month post-RT in patients on steroids at the
initiation of RT. See Table 3 for results of this univariate
analysis. Although no factors were statistically significant
at the alpha = 0.05 level, gender (female vs. male), longer
duration of symptoms prior to RT, total symptom score
prior to RT (≥6 vs. <6), and smoking status did have a
trend towards decreased probability of complete steroid
taper. Eleven patients (12%) experienced long term com-
plications. Chronic dry eye occurred in 9 patients (9.9%)
and cataracts developed in 4 patients (4.4%). Of note,
no patients developed RT induced retinopathy.
Post-radiation therapy surgery
Forty-eight patients (52.7%) underwent surgery after RT.
Nineteen patients (20.9%) underwent bony decom-
pression, 30 patients (33%) underwent lid surgery, and
15 patients (16.5%) underwent EOM recession. One
procedure type was performed in 32 patients, with 16

















Duration of symptoms prior to RT
≤ 6 months 36 39.6
6 – 18 months 38 41.8




Steroid use at initiation of RT
Yes 31 34.1
No 60 65.9











Median age 55 years (range 29 – 84)
RAI= radioactive iodine, RT= radiation therapy.
Table 2 Response to RT by symptom category
Category No. (%) CR No. (%) CR/PR No. (%)
NOSPECS:
Soft tissue 56 (61.5) 8 (14.3) 32 (57.1)
Proptosis 65 (71.4) 4 (6.2) 27 (41.5)
EOM dysfunction 47 (51.6) 13 (27.7) 21 (44.7)
Corneal Involvement 0 (0)
Sight loss 35 (38.5) 7 (20) 13 (37.1)
Diplopia 72 (79.1) 15 (20.8) 38 (52.8)
Orbital pain 38 (41.8) 25 (65.8) 28 (73.7)
Tearing 51 (56) 13 (25.5) 32 (62.7)
RT= radiation therapy, CR= complete response.
PR=partial response, EOM= extraocular eye muscles.
Table 3 Univariate analysis for successful steroid taper
Characteristic Odds ratio 95% CI p-value
Age* 1.03 0.95 – 1.1 0.49
Sex (F vs. M) 0.21 0.04 – 1.3 0.10
Duration of symptoms prior to RT
≤ 6 months reference
6 – 18 months 0.75 0.1 – 5.6 0.78
> 18 months 0.14 0.02 – 1.3 0.08
Total score at diagnosis
(≥ 6 vs. < 6) 0.13 0.01 – 1.2 0.08
Prior steroid use 0.68 0.06 – 7.2 0.75
Response to prior steroids
(PR vs. none) 0.79 0.24 – 2.6 0.70
Current smoking 0.26 0.05 – 1.4 0.12
Total score at 1 month* 0.93 0.6 – 1.4 0.75
* denotes continuous variable.
CI= confidence interval, F= female, M=male, PR=partial response.
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time from the end of RT to decompression, lid surgery,
and EOM recession was 6.2 months (range 2.3 – 17),
10.9 months (range 3.2 – 34.4), and 9.7 months (range
5.9 – 27.1), respectively. Univariate logistic regression
analysis was performed to determine predictors of post-
RT bony decompressive surgery. Potential predictors suchas age, gender, prior or concurrent steroid use, smok-
ing, symptom presentation, total symptom response, and
symptom category response were analyzed. See Table 4
for results of the univariate analysis. Of all of the symp-
tom categories, only objective vision loss at 4 months
was significantly associated with post-RT decompressive
surgery. Variables with a p-value≤ 0.07 in univariate anal-
ysis were included in the multivariate model. However,
objective vision loss at 4 months was not included due
to significant collinearity with total symptom score at
4 months. See Table 5 for the results of the multivariate
logistic regression. Smoking status and total symptom
score at 4 months were independent predictors of post-
RT bony decompression with odds ratios of 3.23 (95% CI
1.03 – 10.2) for current smokers (vs. non-smokers) and
1.59 (95% CI 1.06 – 2.4) for each additional symptom
point at 4 month evaluation. No patient underwent sal-
vage orbital reirradiation.
Table 4 Univariate analysis for post-RT decompressive
surgery
Characteristic Odds ratio 95% CI p-value
Age* 0.97 0.9 – 1.02 0.20
Sex (F vs. M) 0.8 0.3 – 2.6 0.71
Duration of symptoms prior to RT
≤ 6 months reference
6 – 18 months 0.79 0.3 – 2.5 0.69
> 18 months 1.08 0.3 – 4.2 0.92
Total score at diagnosis
(≥ 6 vs. < 6) 2.71 0.9 – 7.9 0.07
Disease severity
Mild reference
Moderate 2.78 0.7 – 10.6 0.14
Severe 3.33 0.4 – 25.4 0.25
Prior surgery 3.89 0.2 – 65.2 0.35
Prior steroid use 1.24 0.5 – 3.4 0.68
Response to prior steroids
(PR vs. none) 0.84 0.2 – 4 0 83
Steroids at initiation of RT 1.17 0.4 – 3.3 0.77
Current smoking 3.6 1.3 – 10.3 0.02#
Total score at 1 month
(> 4 vs. ≤ 4) 3.03 1.04 – 8.9 0.04#
Total score at 4 months* 1.65 1.2 – 2.3 0.003#
Symptoms at diagnosis:
Soft tissue 0.63 0.2 – 1.7 0.37
Proptosis 1.15 0.4 – 3.6 0.81
EOM dysfunction 0.62 0.2 – 1.7 0.35
Objective vision loss 1.59 0.6 – 4.4 0.37
Diplopia 2.63 0.6 – 12.5 0.23
Symptoms at 4 months:
Soft tissue 1.22 0.4 – 3.5 0.70
Proptosis 2.12 0.6 – 7.1 0.22
EOM dysfunction 2 0.7 – 5.7 0.19
Objective vision loss 4.45 1.5 – 12.9 0.01#
Diplopia 1.03 0.4 – 2.9 0.96
* denotes continuous variable, # denotes statistical significance.
RT= radiation therapy, CI= confidence interval, F= female, M=male,
PR=partial response, EOM= extraocular eye muscle.
Table 5 Multivariate analysis for post-RT decompressive
surgery
Characteristic Odds ratio 95% CI p-value
Current smoking 3.23 1.03 – 10.2 0.05#
Total score at diagnosis
(≥ 6 vs. < 6) 0.87 0.2 – 3.8 0.85
Total score at 1 month
(> 4 vs. ≤ 4) 1.22 0.3 – 5.6 0.79
Total score at 4 months* 1.59 1.06 – 2.4 0.03#
* denotes continuous variable, # denotes statistical significance.
RT= radiation therapy, CI= confidence interval.
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The optimal initial local treatment for patients with GO
is not fully characterized, and various treatment modal-
ities including RT, steroids, and surgery have been stud-
ied and found to be effective for symptom palliation and
stabilization. At our institution, we have adopted a policy
of treating patients with moderate to severe GO with RT
with or without steroids as initial local therapy. This
paradigm is meant to use initial RT as a surgery sparingmodality in order to avoid invasive procedures in those
patients who respond to RT. The existing literature con-
cerning the treatment of GO with RT is heterogeneous
and varied, both in terms of study design and results,
but several trends have emerged. It has been established
that RT and steroids have similar efficacy in GO symp-
tom palliation, both primarily affecting soft tissue
involvement and EOM dysfunction, but RT is more tol-
erable and hence should be considered before single
agent systemic steroids [5]. There is also a consensus
that the combination of RT and steroids is more effective
than either modality alone [11]. However, RT as a single
agent has not been well established and several studies
comparing RT with sham RT found minimal difference
between arms, except in response rates for diplopia
[12,13]. We sought to describe our response rates with
RT as initial local therapy as well as determine predictive
factors for the need for salvage orbital decompression.
We demonstrated an overall rate of GO stabilization
or improvement of 92.3% with initial RT, which is com-
parable to other published studies [14]. Response by
symptom category demonstrated heterogeneity of treat-
ment response to RT. Orbital pain, EOM dysfunction,
and tearing had the most robust responses with CR rates
ranging from 25.5% to 65.8%. Pain and tearing were also
the most responsive in terms of overall improvement,
with combined CR/PR rates ranging from 62.7% to
73.7%. In contrast, objective vision loss and proptosis
were the most refractory to RT, with symptom improve-
ment rates (combined CR/PR) of only 37.1% to 41.5%.
This pattern of varying response by symptom category is
in agreement with other similar published studies [15].
These results indicate that the specific constellation of
presenting symptoms may play a role in the choice of
initial local therapy, as it is suggested that patients with
predominantly vision loss and/or proptosis may not have
satisfactory responses to RT.
The prolonged use of systemic steroids is associated
with a significantly increased risk of a variety of potential
side effects [5]. 31 patients (34.1%) were on steroids at
the initiation of RT. A primary goal of RT is to achieve a
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tapering of steroids prior to the development of toxicity.
Of the initial 31 patients, 23 (72.4%) were able to be
successfully tapered by 2 months post-RT, prior to any
surgical intervention. This is lower than other published
studies [10], but our completely tapered rate is solely
in response to RT, as opposed to after RT and salvage
surgery in other series. We performed a logistic regres-
sion analysis to determine predictors for successful
steroid taper. Although no factors were statistically sig-
nificant, gender (female vs. male), longer duration of
symptoms prior to RT, higher total symptom score at
diagnosis (≥6 vs. <6), and current smoking trended
towards less probability of complete steroid taper by
2 months post-RT. The lack of statistical significance
may be due to the small number of patients on steroids
at the initiation of RT.
The overall salvage surgery rate after radiation therapy
in this series was 52.7%. The rates of bony decompres-
sion, EOM recession, and lid retraction repair were
20.9%, 16.5%, and 33%, respectively. This is similar to a
series by Gorman et al., where the overall salvage sur-
gery rate was 50%, and the rates of decompression,
EOM recession, and lid retraction repair were 19%, 26%,
and 43%, respectively [16]. Orbital decompression is an
invasive procedure that has reported risks of complica-
tions, including facial parethesias, sinusitis, diplopia, and
vision loss, as high as 10 - 17% [17]. The use of RT as
initial local therapy is an attempt to minimize the need
for orbital surgery, specifically orbital decompression.
We performed a logistic regression analysis in order to
better define predictors of post-RT bony decompression.
The symptom category found to be most associated with
the need for salvage decompression was objective vision
loss at 4 months post-RT. Considering that objective
vision loss was relatively refractory to RT with an overall
response rate of only 37%, combined with the associ-
ation between persistent vision loss and the need for
decompression, our data suggest that patients presenting
with objective vision loss should be advised of their
worse prognosis and elevated risk of salvage decompres-
sion. The crude rate of bony decompression in patients
with vision loss at 4 months was 40%, approximately
twice the rate of the entire study population. Conversely,
60% of these patients did not undergo salvage decom-
pression after initial RT, suggesting that the majority of
these higher risk patients can still be spared eventual
surgical intervention with this treatment paradigm. In
addition, it has been reported that previous RT with or
without steroids does not adversely affect the outcome
of eventual decompressive surgery [18].
A multivariate logistic analysis demonstrated that
smoking at the time of RT and total symptom score at
4 months are independently associated with the need forsalvage bony decompression. Smoking is not only ap-
proximately 1.5 times more prevalent among those with
Graves’ disease and 2 times more prevalent among those
with GO [2], but current smoking also has a detrimental
effect on palliative response to RT [19]. Our study
demonstrates that the detrimental effects of smoking
extend further to include a significantly increased risk
of post-RT decompressive surgery. It is not currently
known what time period is required after the cessation
of smoking to decrease the risks of reduced response
to RT and higher rates of salvage surgery, but our
data indicate that patients with GO who are currently
smoking should be extensively counseled about these
increased risks and attempts should be made to facilitate
smoking cessation.
Orbital RT was well tolerated in our series with no
patients requiring treatment breaks for acute toxicity.
Long term toxicity was manageable with 11 patients
(12%) experiencing long term complications. Nine
patients developed chronic dry eye, with all patients suc-
cessfully medically managed. Four patients developed
cataracts, all of whom underwent successful cataract
removal and lens replacement. These rates of long term
complications are similar to other published series [10].
However, these rates may represent an overestimation of
RT toxicity as other known factors, such as age, medical
comorbidities, and steroid use, can all contribute to this
spectrum of long term complications. Importantly, no
patients developed radiation retinopathy.
There are a limited number of reports in the literature
describing the natural history of GO, but a potential
criticism of RT (or surgery) as initial local therapy is the
possibility of spontaneous improvement in GO symp-
toms with conservative management. An observational
study of 59 patients with GO with a median follow-up
period of 12 months found that 64% of patients experi-
enced spontaneous improvement in their GO symptoms
without local therapy or immunosuppressant use [20].
However, the severity of symptoms in this observational
study was significantly less than in our study popula-
tion, and patients in our study with duration of
symptoms ≤ 6 months had generally already failed prior
observation and/or steroid therapy.
A potential criticism of RT as initial local therapy,
especially in patients who have not had a trial course of
steroids, is the theoretical increased risk of secondary
malignancy. The excess lifetime risk of radiation induced
fatal cancer after RT for GO was estimated to be 7 cases
per 1000 persons (0.7%) [21]. The excess lifetime risk of
any radiogenic carcinoma was estimated to be possibly
as high as 1 – 1.4%. However, these estimations were
determined with the assumption of an excess lifetime
fatal radiogenic cancer risk of 10% per Sievert (Sv). The
median age of our study population was 55 years old,
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45 years. The estimated excess lifetime fatal radiogenic
cancer risk for patients of this age range is only 6% per
Sv, and decreases with older age at the time of RT. This
theoretical risk was felt to be acceptable in this patient
population with moderate to severe GO symptoms.
The duration of follow-up was not sufficient to formally
assess risk of secondary malignancy, though no patients
did develop a malignancy of the head or neck region
during the follow-up period.
Conclusions
Orbital RT is an established and safe modality for the
treatment of GO. Most patients experience stabilization
or improvement of GO symptoms, but moderate to sig-
nificant response occurs in the minority of patients. The
response of specific symptom categories to RT is varied,
with objective vision loss and proptosis being the most
refractory. Most patients are able to completely taper
off steroids by 2 months post-RT, although female
gender, longer duration of symptoms prior to RT, higher
symptom score at diagnosis, and smoking trended
towards an association with inability to taper steroids.
Persistent objective vision loss at 4 months is the
symptom category most predictive of salvage bony
decompression. Current smoking and higher 4 month
symptom score are independently associated with a sig-
nificantly elevated probability of post-RT decompressive
surgery. Patients who smoke or present with predomin-
antly vision loss symptoms should be advised as to their
lower likelihood of symptomatic response to RT and
their increased likelihood of requiring post-RT decom-
pressive surgery. RT with or without steroids as initial
local therapy is a viable treatment paradigm for the
majority of patients presenting with GO.
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